Post 5-fluorouracil-treated murine bone marrow cells infected with a recombinant retrovirus (murine stem cell virus-interleukin 11 [MSCV-IL-11]) bearing a human IL-11 gene were transplanted into lethally irradiated syngeneic mice. Analysis of proviral integration sites in DNA prepared from hematopoietic tissues and purified cell populations of long-term reconstituted primary and secondary recipients demonstrated polyclonal engraftment by multipotential stem cells. High levels (100-1,500 U/ml) of IL-11 were detected in the plasma of the MSCV-IL-11 mice. Systemic effects of chronic IL-11 exposure included loss of body fat, thymus atrophy, some alterations in plasma protein levels, frequent inflammation of the eyelids, and often a hyperactive state. A sustained rise in peripheral platelet levels (•l.5-fold) was seen throughout the observation period (4-17 wk) . No changes were observed in the total number of drculating leukocytes in the majority of the transplanted animals (including 10 primary and 18 secondary recipients) despite a >20-fold elevation in myeloid progenitor cell content in the spleen. The exceptions were members of one transplant pedigree which presented with myeloid leukemia during the secondary transplant phase. A clonal origin of the disease was determined, with significant expansion of the MSCV-IL-11-marked clone having occurred in the spleen of the primary host. Culturing of leukemic spleen cells from a quaternary recipient led to the establishment of a permanent cell line (denoted PGMD1). IL-11-producing PGMD1 myeloid leukemic cells are dependent on IL-3 for continuous growth in vitro and they differentiate into granulocytes and macrophages in response to granulocyte/macrophage colony-stimulating factor. The inability of autogenously produced IL-11 to support autonomous growth of PGMD1 cells argues against a mechanism of transformation involving a classical autocrine loop.
I
nteraction between hematopoietic and stromal cells in the bone marrow is important for the maintenance of steadystate hematopoiesis (1) . IL-11 is a recently identified multifunctional stromal cell-derived factor whose actions on cells of the hematopoietic and immune systems implicate it as a potential contributor to this process (2) .
A cDNA encoding IL-11 was originally isolated from the PU-34 primate bone marrow stromal cell line based on an activity in the culture supernatant that stimulated the proliferation of IL-6-dependent Tl165 routine plasmacytoma cells (3, 4) . The identification of IL-11 through the use of an IL-6 bioassay prompted the testing of this cytokine in other IL-6-responsive systems. The results of these studies have confirmed that IL-11 and IL-6 possess overlapping biologic properties. Like IL-6, IL-11 has megakaryocytopoietic and thrombopoietic functions (4) (5) (6) (7) (8) . In addition, IL-11 has been shown to synergize with IL-3, IL-4, or the ligand for the c-kit receptor to promote the growth of blast colony-forming cells (CFC) l, an effect previously described for IL-6 and G-CSF (9) (10) (11) . IL-11 also shares with IL-6 the ability to augment antigen-specific antibody responses (12) . Outside the hematopoietic system, activities common to both IL-11 and IL-6 have been described on hepatocytes, preadipocytes, and neuronal cells (13) (14) (15) (16) .
There have been a limited number of reports of in vivo effects of IL-11 on hematopoiesis. Administration of IL-11 to mice accelerated platelet and neutrophil recovery after bone marrow transplantation (7) . By comparison, short-term treatment of normal mice with IL-11 resulted in modest increases in peripheral platelet levels above those of vehicle-treated controls (*1.3-fold) with minimal effects noted on circulating neutrophil numbers (8, 17, 18) . These findings are comparable to those obtained by in vivo administration of IL-6 (19) (20) (21) , but contrast sharply with the striking changes we observed in mice chronically exposed to high plasma concentrations of IL-6 after engraftment with bone marrow cells constitutively expressing a retrovirally introduced IL-6 gene (22) . The IL-6 transplant mice uniformly developed a fatal myeloproliferative syndrome characterized by neutrophil excess (up to 400 • 103 cells/mm3), microcytic anemia, thrombocytosis followed by thrombocytopenia, and marked alterations in plasma protein levels. In general, these hematologic changes were greater than had previously been seen in other IL-6 animal models (23, 24) . Thus, in the present study, we used our retroviral delivery system to examine the long-term hematologic consequences of dysregulated IL-11 expression.
Materials and Methods
Murine Stem Cell Virus (MSCV)-IL11 Retrovirus Vector and Cell Lines. The MSCV-IL-11 vector (see Fig. 1 A) was constructed by inserting a 0.8-kb EcotLI-BgllI fragment of a human Ib11 cDNA (4) into the corresponding sites of the polylinker in the MSCV vector (version 2.1 has unique EcoRI, HpaI, XhoI, and BglII sites) (22) . The salient features of the MSCV vector design include variant LTRs and modified 5' untranslated sequences conferring efficient LTR-directed expression in primitive cells, an extended packaging region (~ +) for high viral titer containing mutations that abolish the synthesis of any gag-related polypeptides and eliminate the need for splicing to express inserted genes, and the absence of all envelope sequences, thereby abrogating the possibility of homologous recombination with corresponding sequences of endogenous retroviruses. The neomycin phosphotransferase (neo) gene in MSCV v2.1 contains a synthetic initiation sequence favorable for translation in mammalian cells and has been placed under the transcriptional control of an internal phosphoglycerate kinase (pgk) promoter for constitutive expression in a wide range of cell types (25) . Plasmids were constructed using standard techniques (26) .
Recombinant virus was produced from clones of GP+E-86 ecotropic helper-free packaging calls (27) , generated as described previously by infection of tunicamycin-treated cells with supernatant from transient transfectants (22) . The cell line used for all gene transfer experiments, GP+E-86/MSCV-Ib11 c3, produces structurally intact MSCV-Ib11 virus with a titer of 4 x 106 G418-resistant CFU/mlwhen assayed on NIH3T3 fibroblasts. Cells were maintained in DME with 4.5 g/1 glucose (GIBCO BILL, Gaithersburg, MD) supplemented with 10% calf serum (Hyclone Laboratories, Logan, UT) in a humidified atmosphere containing 5% CO2 at 37~
Retrovirus Infection and Transplantation of Bone Marrow. Female BALB/c mice (Charles River Laboratories, Montreal, Canada) were used at 6-8 wk of age as bone marrow donors and recipients. Bone marrow processing, infection, and transplantation were carried out according to established procedures (22, 28) . In brief, bone marrow was flushed from hind limbs of donors injected 4 d previously with 150 mg/kg 5-fluorouracil (Hoffmann-La Roche Ltd., Mississauga, Canada) with ice-cold IMDM containing 50/~M 2-ME and 10% heat inactivated FCS (GIBCO BILL). After erythrocyte lysis in 0.17 M ammonium chloride, nucleated cells were added to 100 mm petri dishes (Fisher Scientific Co., Pittsburgh, FA) at a density of 5 x 10 s cells/ml in IMDM supplemented with 50/~M 2-ME, 10% heat-inactivated FCS, 10% conditioned medium from X630-rlL3 cells (a source of IL-3; a gift of F. Melchers, Basel, Switzerland) (29) , and 10% conditioned medium from Sp2/mlb6 cells (a source of Ib6) (30) . After 48 h, the bone marrow cells were collected and added to subconfluent monolayers of GP+E-86/ MSCV-Ib11 c3 cells in lO0-mm tissue culture dishes (Nunc, Roskilde, Denmark) at a density of 5 x 10 s cells/ml in fresh medium supplemented with 8/~g/ml polybrene. After a further 48 h, nonadherent bone marrow cells were harvested and incubated in cocultivation medium containing 0.75 mg/ml (actual concentration) G418 (GIBCO BRL). These calls were collected 24 h later and injected via the tail vein into recipients that had received 7 Gy of irradiation (gammacell 1000; Atomic Energy of Canada Ltd., Kanata, Ontario, Canada). Each mouse received between 5 x 10 s and 2 x 106 ceils (seven donor equivalents per recipient). For serial transplantations, 10 6 bone marrow cells from affected animals were injected intravenously into lethally irradiated (7 Gy) recipients. Mice were housed one to four per sterilized microisolator cage on laminar flow racks. The colony was periodically tested for a panel of viruses by analysis of serum samples (Charles River Laboratories Diagnostic Services, Wilmington, MA). Animals tested negative for sendai virus, pneumonia virus of mice, mouse hepatitis virus, minute virus of mice, mouse polio virus and reovirus type 3. The animals were also found to be free of mycoplasma.
Hematologic and Pathologic Analysis. Blood was collected from the retroorbital sinus at weekly/biweekly intervals after transplant and immediately before death. Total leukocytes, total erythrocytes, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width, total phtelets, and mean platelet volume were determined on a System 9000 Hematology Series Cell Counter (Serono-Baker Instruments, Allentown, PA) equipped with a veterinarian software package (22) . Controls were mice transplanted with hematopoietic cells infected with other MSCV viruses as well as age-matched littermates.
Mice were killed by cervical dislocation and necropsy examinations were performed immediately after death. Tissues were preserved in 10% neutral-buffered formalin overnight, then embedded in paraffin, sectioned, and stained with hematoxylin and eosin before examination by light microscopy (22) . Tissues examined included spleen, thymus, lungs, heart, liver, pancreas, stomach, intestines, kidneys, lymph nodes, sternum (bone marrow), and eyelids.
In Vitro Progenitor Cell Assay. The number of CFC was determined by plating nucleated bone marrow (at 104 and 2 x 104 cells/ml) and spleen calls (at 2 x 104 and 4 x 104 cells/m1) in duplicate 1-ml cultures (35-ram Lux suspension plates; Nunc, Inc., Naperville, IL) containing cx-MEM, 0.8% methylcellulose, 30% FCS, 1% BSA, 100/~M 2-ME, 3 U/ml erythropoietin, and 1% FWM-stimulated spleen conditioned medium (a source of IL-3 and GM-CSF; Terry Fox Laboratory, Vancouver, Canada) as described (31) . Where indicated, G418 was added to a final concentration of I mg/ml. Colonies (consisting of more than 50 cells) of granulocytes, macrophages, erythroid cells, and mixtures of these with megakaryocytes were enumerated using an inverted microscope on day 7 and recorded together as CFC.
Isolation of Primary Cdl Populations.
To generate populations enriched for mast cells (adherent and nonadherent), bone marrow or spleen cells were cultured in 100-mm tissue culture dishes in IMDM supplemented with 50/zM 2-ME, 10% heat-inactivated FCS, 10% conditioned medium from X630-rIL3 cells, and 0.75 mg/ml G418 for 3-4 wk. Populations of macrophages were prepared by culturing bone marrow or spleen cells for 48 h in IMDM supplemented with 50 #M 2-ME, 10% heat-inactivated FCS, 10% conditioned medium from X630-rlL3 calls, and 20% conditioned medium from L929 cells (a source of CSF-1), transferring the nonadherent cells to dishes containing IMDM supplemented with 50 #M 2-ME, 10% heat-inactivated FCS, 30% conditioned medium from L929 cells, and 0.75 mg/ml G418, and culturing for periods of up to 4 wk. T cell populations were obtained by culturing spleen cells in tLPMI 1640 medium (GIBCO BILL) supplemented with 50 #M 2-ME, 10% heat-inactivated FCS, 10% conditioned medium from X630-rIL2 ceils (a source of IL-2; a gift of F. Melchers) (29) , 10% conditioned medium from X630-rlL4 ceils (a source of Ib4; a gift ofF. Melchers) (29), 5 #g/m1 Con A, and 0.75 mg/ml G418 for more than 3 wk. The various cell populations were judged to be >90% pure by cytochemical and immunological criteria (32, 33) .
Bioassays. IL-11 activity in culture supernatants and plasma samples was detected by T10 microproliferation assay (a gift of F. Bennett, Genetics Institute) (34) . The cells were propagated in ILPMI 1640 medium supplemented with 50/zM 2-ME, 10% heatinactivated FCS, and 20 U/m1 recombinant human IL-11. Purified recombinant human Ib11 (a gift of P. Schendel, Genetics Institute) was produced in Escherichia coli and had asp act of 2. IL-6 activity in plasma samples was tested for by B9 microproliferation assay (36) essentially as described (22) .
Microwell cultures of 32D and OTT1 cells were similarly used to assay IL-3 and GM-CSF as described (37) . OTT1 murine myeloid cells which are dependent for their survival and proliferation on one of IL-3, GM-CSE or IL-5 were obtained from primary cultures of murine bone marrow infected with a retrovirns vector carrying a murine IL-lot cDNA and the bacterial neo gene (33) . The subdone (c12) used is propagated in IMDM supplemented with 50 #M 2-ME, 10% heat-inactivated FCS, and 10% conditioned medium from X630-rIL3 cells" murine Pam 212 keratinocyte cells (a source of GM-CSF; a gift of R. McKenzie and D. Sauder, Sunnybrook Health Science Centre) (38) or X630-rlL5 calls (a source of IbS; a gift of F. Melchers) (29) .
Cellulose Acetate Electwphoresis of Plasma Samples. Electrophoretic separations of plasma proteins were performed in barbital-sodium barbital buffer according to the manufacturer's instructions (Sepratek System; Gelman ,Sciences, Inc., Ann Arbor, MI). Briefly, electrophoresis was for 20 min at 225 V on cellulose acetate strips soaked in the buffer for 10 min before sample application. After electrophoresis, the strips were stained and fixed for 10 min in 0.5% Ponceau S/7.5% trichloroacetic add, destained for 15 rain in 5% acetic add, and cleared in 40.0% aqueous N-methyl pyrrolidone before photography.
Nucleic Acid Analysis. Southern and Northern blot analyses were carried out according to standard procedures (26) . High molecular weight DNA (10 #g) was digested with EcoRI (which cleaves uniquely within the vector) and proviral junction fragments were identified by Southern blotting using a 1.0-kb BgllI-SmaI fragment of the neo gene as probe (39) . Total cellular (10 #g) or poly(A) + (1 #g) KNA was analyzed by Northern blotting for viral RNA transcripts using a 0.8-kb EcoRI-BgllI fragment of a human IL-11 cDNA (4) and a 1.0-kb BgllI-SmaI fragment of the neo gene as probes. Endogenous IL-6 transcripts were detected with a probe consisting of a 0.6-kb EcoRI-BglII fragment of a murine IL-6 cDNA (40). Other probes used were restriction fragments obtained from the following plasmids: p17.4 (carrying a cDNA encoding the murine Mac-1 ~2 integrin subunit; 63056; American Type Culture Collection, Rockville, MD [ATCC]); K4-1.1 (carrying a murine intercellular adhesion molecule 1 (ICAM-1) cDNA; 63043, ATCC); pMC1 (carrying murine c-myb genomic sequences; 41056, ATCC); pSVc-mycl (carrying the second and third exons of the murine c-myc gene; 41029, ATCC); and p465.20 (carrying a murinejunB cDNA; 63025, ATCC). The amount and integrity of RNA loaded was monitored by hybridization with a probe recognizing glyceraldehyde-3-phosphate dehydrogenase sequences (41) .
Results
Infection of lL-6-dependent B Cell Lines. The T10 cell line is a derivative of the IL-6-dependent Tl165 plasmacytoma that wiU also grow in medium supplemented with IL-11 (34) . To demonstrate MSCV-IL-11-encoded production of functional IL-11, T10 cells were infected by exposure to helperfree recombinant virus produced by a donal isolate of GP+ E-86 packaging cells and examined for conversion to factor-independent growth. IL-6-dependent murine B9 hybridoma cells (36) were also infected with MSCV-IL-11 since testing of several factor-dependent cell lines revealed IL-11 to have mitogenie activity for these ceUs (our unpublished results). G418-resistant populations of MSCV-IL-11-infected T10 ceils were readily established and could be maintained in the absence of an exogenous source of IL-11, indicating successful transmission of functional vector sequences. Notably, G418-resistant populations of MSCV-IL-11-infected B9 ceils were also converted to growth factor autonomy. Conditioned medium prepared from culture supematants ofT10 and B9 infectants supported the long-term growth of T10 cells. Northern blot analysis of poly(A) § RNA from infectants with an IL-11 probe revealed, as expected, a 3.6-kb transcript originating from the MSCV-IL-11 LTK (Fig. 1 B) . Rehybridization of the blot with a routine IL-6 probe failed to detect any endogenous IL-6 mKNA species (Fig. 1 B) . To investigate whether autogenous IL-11 synthesis could facilitate in vivo growth of IL-6-dependent ceils, syngeneic BALB/c mice were inoculated subcutaneously (106 cells/site) with pools of infectants and corresponding parental cell lines. As shown in Table 1 , compared to parental T10 ceils, T10 infectants formed tumors at a much higher frequency and with a much shorter latency period. The in vivo growth potential of IL-6-dependent B9 cells (42) was also enhanced by constitutive IL-11 synthesis. MSCV-IL-11-infected B9 ceils exhibited a decreased latency period of tumor development that was comparable with that observed for B9 derivatives producing autocrine retrovirally encoded IL-6. Collectively, the results show that IL-11 can act as an autocrine growth factor for certain IL-6-dependent murine B cell lines via a mechanism that does not involve endogenously synthesized IL-6.
IL-11 Expression in Long-Term Reconstituted Mice.
Lethally irradiated BALB/c mice received intravenous inoculations of MSCV-IL-11-infected bone marrow cells (106 cells) according to a protocol previously used (22) to generate transplant mice having excessive circulating levels of IL-6. Plasma obtained from all primary and secondary MSCV-IL-11 mice examined 5-16 wk after transplantation, but not from control mice, exhibited significant activity in the T10 bioassay (mean values of 500 U/ml IL-11 equivalents; range, 100-1,500 U/ml; n = 10). The T10 stimulatory activity could not be inhibited by a neutralizing antibody to murine IL-6 (Fig. 2 top) . This finding plus the fact that plasma from both MSCV-IL-11 and control mice had minimal stimulatory activity when assayed on IL-6-dependent B9 cells (<0.1 ng/ml IL-6) ruled out the possibility that the T10 response was mediated by endogenous IL-6. Recent experiments demonstrating >90% inhibition of plasma-induced T10 proliferation by a neutralizing anti-IL-11 antibody (a gift of E. Alderman, Genetics Institute) have established the identity of the active species as IL-11 (data not shown).
Northern blot analysis of total spleen RNA demonstrated sustained expression of the 3.6-kb viral IL-11 mRNA for periods of up to 16 wk in secondary recipients (Fig. 3 A) . No endogenous IL-6 mRNA transcripts were detected upon rehybridization of the blot with a probe specific for murine IL-6 coding sequences (Fig. 3 A) .
The clonal composition of the reconstituted hematopoietic systems of MSCV-IL-11 transplant mice was examined by Southern blot analysis of EcoRI-digested DNA with a neo probe. Since EcolLl cleaves the MSCV-IL-11 provirus once (Fig. 1 A) , each band represents a unique integration site. As illustrated in Fig. 3 B, genomic DNAs from hematopoieric tissues (bone marrow and spleen) and purified G418-resistant cell populations (macrophages, mast cells and T cells) of a representative primary recipient (mouse 96, reconstituted for 12 wk) and two secondary recipients (mice 95.1 and 95.2, reconstituted for 12 wk with bone marrow from a primary mouse reconstituted for 16 wk) contained many fragments that hybridized to the neo probe. The presence of common bands in lanes containing DNA samples from lymphoid and myeloid lineage cells, as well as bands identifiable in only some of the lanes, indicated polyclonal repopulation by primitive MSCV-IL-11-infected hematopoietic cells, a subset of which were multipotential stem cells. 
Hematologic Changes in MSCV-IL-11 Transplant Mic~
The main consequence of persistent IL-11 expression was a sustained rise in platelet levels (1.5-1.6-fold higher than corresponding values obtained for normal and control transplant mice, respectively) throughout the observation period (Table  2 ; Fig. 4 ). Since this increase could not be attributed to IL-6, the possibility was considered that IL-11 may have induced elevations of IL-3 or GM-CSF, two factors with known in vivo actions on megakaryocytes (43, 44) . However, no IL-3 or GM-CSF activity was detectable by 32D or OTT1 microproliferation assays (33, 37) in the plasma of any mice tested. On the basis of results from in vitro studies (4-6), the observed changes in platelet levels might be due in part to IL-11 acting in collaboration with low amounts of these factors. To address this issue, current experiments are examining cytokine gene mRNA profiles in MSCV-IL-11 mice by RT-PCR.
Long-term exposure to high circulating levels of IL-11 resulted in minimal changes in other peripheral blood cell values (Table 2) . Differential leukocyte counts showed a neutrophilic predominance (mean, 70%) but there was no increase in total leukocyte numbers. Although in vitro erythropoietic properties of IL-11 have been recognized (45) , the in vivo effects of IL-11 on circulating erythrocyte values were minor. In fact, hematocrits were slightly reduced compared with those of normal mice because of a small decrease in mean corpuscular volume. The significance of this is unknown, however, since hematocrit values did not differ meaningfully from values obtained for control transplant mice.
In view of the relatively normal peripheral blood cell counts in MSCV-IL-11 mice, it was notable that enhanced hematopoiesis was observed in bone marrow and spleen (Fig. 5) . This was most striking in the case of the spleen where there was a concomitant 12-56-fold elevation in total progenitor cell content ( Table 3 ). As spleen weight was increased about twofold (Table 3) , the actual total increase per spleen in progenitor cell numbers was 20-100-fold. Detailed cytological analyses of colonies formed in methylcellulose-containing medium were not carried out, but no conspicuous differences between MSCV-IL-11 and control mice in the relative distribution of the various progenitor subpopulations were apparent upon gross inspection of cultures. Although high percentages (31-68%) of CFC found in the spleens of both primary and secondary recipients were G418 resistant (Table 3) , substantial expansion of G418-sensitive progenitors also occurred, indicating that paracrine mechanisms contributed to the phenomenon. Associated with the general rise in splenic hematopoiesis was a minor elevation in spleen megakaryocyte numbers in correspondence with the higher blood platelet levels.
Other Effects of Dysregulated IL-11 Expression.
A uniform finding in MSCV-IL-11 mice was a 15-20% reduction in body weight (Table 3) , often accompanied by a hyperactive state. Upon autopsy, it was observed that the decrease in body weight was due to the loss of subcutaneous and intraabdominal fat, an effect presumably of the lipoprotein lipase inhibitory activity of IL-11 (14, 15) . MSCV-IL-11 mice routinely developed inflammatory eyelid lesions characterized grossly by marked swelling and erythema. Histologic analysis revealed acute inflammation on the surface of the conjunctival mucosa. Other consistent changes included thymus atrophy and frequent distention of the stomach or bowel with noticeable alterations in muscle tone. No significant changes were noted in liver or kidney and histologic examination of these organs failed to reveal any abnormalities.
Cellulose acetate electrophoresis of plasma samples from MSCV-IL-11 mice revealed changes in acute phase protein levels, including slight reductions in albumin levels with increases in protein levels in the ol2-macroglobulin/haptoglobin region, that were much less pronounced than those observed in mice overexpressing IL-6 (Fig. 2, bottom) . Measurement of amounts of plasma proteins by rocket immunoelectrophoresis (46) indicated that albumin levels were in the normal range whereas haptoglobin levels were significantly higher See Table 2 for values of all hematologic parameters examined.
(mean values of 9.4/~g/ml; range, 7.2-11.0/xg/ml; n --8) than normal (<1/zg/ml). These results indicate that IL-11 can function as a regulator of the hepatic acute phase response in mice (13) .
Myeloid Leukemia Development after Serial Transplantation of MSCV-IL-11-infected Hematopoietic Cells. 6 wk after trans-
plantation with bone marrow cells from mouse 74, decreased platelet levels were detected in two secondary recipients. By 8 wk, both animals were severely thrombocytopenic (platelet counts ",q30 x 103/ram3). One mouse (mouse 74.1) had lower than normal peripheral leukocyte counts (3.6 x 103/ mm 3) whereas the other animal (mouse 74.2) presented with leukocytosis (43.6 x 103/mm3). At necropsy, both mice were found to have considerably enlarged spleens (spleen weights of 0.364 and 0.498 g). Bone marrow (2 x 106) or spleen (5 x 106) cells from these mice were leukemogenic within 4 wk of transplant into sublethally irradiated (4.5 Gy) tertiary recipients. The characteristic features of the malignant disease included leukocytosis with neutrophil bias (>200 x 103 cells/mm 3) and evidence of blasts in the peripheral blood, anemia (mean hematocrits, 27%), thrombocytopenia (mean platelet counts, 56 x l(P/mm3), and splenomegaly (mean spleen weights, 0.65 g). Histopathologic analysis of the spleen from diseased mice showed effacement of the splenic architecture by cytologically abnormal cells (Fig. 6 B) .
Attempts to establish factor-dependent or autonomously growing cell lines in liquid culture from spleen ceils of tertiary 74-series recipients were unsuccessful. However, in vitro culture of spleen cells from one quaternary recipient (mouse 74.1.1.1) yielded an IL-11-producing yet IL-3-dependent cell line (denoted PGMD1, Fig. 6 C) . An immature myeloid phenotype was determined by flow cytometric analysis of cell * Secondary recipients of MSCV-IL-11-infected bone marrow are denoted by the number of the primary recipient followed by a unique numeric extension. MSCV-X and BALB/c values represent the mean and SE of values obtained for six other MSCV transplant mice (as per Table 2 footnotes) and for six normal mice, respectively. * CFC frequency per 106 cells.
surface markers. PGMD1 cells express high levels of the leukocyte common antigen Ly-5 (CD45), high levels of the Fc receptor for aggregated IgG (CD32), low levels of the myeloid integrin Mac-1 (CDllb), and low levels of the cell adhesion molecule ICAM-1 (CD54), but no detectable amounts of Ia antigen. Intravenous inoculation of PGMD1 cells into sublethally irradiated syngeneic BALB/c mice gave rise to myeloid leukemia (four of five mice that received 5 x 106 cells developed tumors by 6 too). The fact that in vivo-passaged PGMD1 cells maintained their factor dependency upon reintroduction into liquid culture (data not shown) suggests that the leukemic disease in 74-series mice occurs via a paracrine mode of growth stimulation. Southern blot analysis of proviral insertion pattern showed that DNA from the PGMD1 cell line and spleen DNAs from all 74-series mice contained four predominant bands (Fig. 6  A) . We interpret this result to mean that the myeloproliferative disease that developed in this transplant pedigree originated in the clonal descendant of a hematopoietic precursor harboring four MSCV-IL-11 proviruses. Although the clone represented the major MSCV-IL-11-positive cell population in the spleen of primary mouse 74, it did not appear to be overtly malignant at this time as indicated by the absence of abnormal cells in histologic sections or of atypical colony formation in metbylcellulose culture (Table 3) . Even after the development of frank malignancy, further clonal evolution was apparently necessary before successful adaptation for growth in culture. Culture supernatant from PGMD1 cells tested negative for the presence of infectious virus in a sensitive marker virus mobilization assay (32, 47) , arguing against insertional mutagenesis by packaging line-generated or spontaneously activated endogenous retroviruses.
Unlike other IL-3-dependent murine myeloid leukemic cell lines (48) , PGMD1 cells can be induced to differentiate into macrophages and/or granulocytes by GM-CSF or G-CSF (Fig.  6 D; other data not shown). Analysis of gene expression patterns during GM-CSF-induced myeloid differentiation revealed upregulated expression of IL-6, Mac-l, ICAM-1, andjunB mRNAs and decreased expression ofc-myb and c-m),c mRNAs (Fig. 6 E) . This genetic response is reminiscent of that observed when autonomously proliferating M1 murine myeloid leukemic cells are stimulated to terminal differentiation by IL-6 (49).
Discussion

IL-II as a Thrombopoietic Factor in Mice.
To investigate the in vivo hematopoietic activities of IL-11, we generated chimeric mice whose hematopoietic systems had been reconstituted for extended periods of time with genetically modified bone marrow cells constitutively expressing IL-11. The major effect of high circulating IL-11 levels was a chronic 1.5-fold increase in peripheral platelet counts. This finding confirms and extends previous reports (4-8) of megakaryocytopoietic and thrombopoietic activity oflL-11. In a recent publication (8), C57BL/6 mice injected subcutaneously with 1.5 #g of IL-11 twice a day for 7 d showed a 1.3-fold elevation in peripheral platelet counts compared with vehicle-treated controls. In that study, rapid clearance of IL-11 from the circulation upon cessation of the dosing regimen resulted in platelet counts returning to normal values by day 15. Because there were no other consistent hematologic changes, the modest thrombopoietic response elicited could have been due to suboptimal circulating IL-11 concentrations. In the present series of experiments, it is unlikely that IL-11 amounts are limiting in this respect. Although spleen megakaryocyte numbers were slightly elevated in MSCV-IL-11 mice, observations in splenectomized mice would suggest that splenic megakaryocytopoiesis does not contribute substantially to the increase in peripheral platelets effected by IL-11. Rather, as documented previously (8) , the higher peripheral platelet counts are probably the result of IL-11-induced enhancement of megakaryocyte progenitor numbers and IL-11-stimulated endoreplication of megakaryocytes in the bone marrow.
It is noteworthy that sustained high level IL-11 expression had little impact on peripheral leukocyte or erythrocyte values, the exceptions being a neutrophilic shift in the differential and a reduction in mean corpuscular volume, respectively. In other work (7, 17) , daily administration of IL-11 to mice during bone marrow reconstitution accelerated the recovery of peripheral leukocytes, mainly neutrophils, in addition to platelets. Moreover, early recovery of erythrocytes was observed in another study in mice (50) transplanted with bone marrow cells infected with a different IL-11-expressing retrovirus. One interpretation of these results is that IL-11 acts synergistically with certain cytokines induced after hematopoietic injury or expressed by the reconstituting cells that are not normally present in high concentrations during steadystate hematopoiesis. This interpretation would be consistent with the demonstrated synergistic interactions between IL-11 and multiple cytokines in various in vitro assays and a general lack of observed activity when it is used as a single agent (2) . Future work will investigate the rate of recovery of peripheral leukocytes and erythrocytes in transplant recipients receiving MSCV-IL-11-infected bone marrow.
It should be noted that a transient 1.5-fold increase in leukocyte counts, primarily due to a sevenfold increase in neutrophils, was seen in B6D2F1 mice that received subcutaneous injections of 4 gg of IL-11 twice a day for 10 d (18) . As well, bone marrow cells from B6D2Ft mice formed significant numbers of macrophage colonies in methylcellulose when plated into medium containing IL-11 and erythropoietin (9), indicating that IL-11 can directly support the proliferation of some committed macrophage progenitors in that mouse strain. A possible reason therefore for the numbers of circulating leukocytes remaining relatively unchanged in this animal model could be strain-specific differences in IL-11 responsiveness. The use of the BALB/c mouse strain might explain why blood erythrocyte counts were not markedly elevated despite the ability of IL-11 to promote maturation of late erythroid progenitors in bone marrow cultures derived from mice of some other strains (45) . This explanation is not completely satisfactory, however, in light of the enhanced splenic hematopoiesis observed. If anything, the in vivo situation is probably complex and other possibilities, for example, that constant high level IL-11 expression induces activities which are inhibitory to steady-state hematopoiesis (51) , need also to be considered. Erythrokinetics would also be expected to be negatively affected by IL-11-induced alterations in splenic function and plasma composition (52) .
Pleiotwt~ and Redundancy. Interestingly, the in vivo effects of high sustained concentrations oflL-11 were less like those of IL-6 (22) and were more like those of another pleiotropic cytokine, leukemia inhibitory factor (LIF) (53) . Injection of mice with LIF (2 #g three times daily for 14 d) resulted in elevated numbers of circulating platelets, a moderate increase in spleen weight with an associated rise in the numbers of various subsets of splenic progenitors, a small decrease in hematocrit, and thymus atrophy. Nonhematopoietic effects included behavioral changes (hypermobility and irritability), weight loss due to reduction in fatty tissue, distended stomachs, and increased erythrocyte sedimentation rate and elevated calcium/albumin ratios characteristic of the acute phase protein reaction. There are differences, however, between IL-11 and LIF. For example, LIF appears to be more toxic than IL-11 since several of the mice injected with LIF died. Moreover, chronic exposure of mice to high levels of LIF (plasma concentrations of '-1,000 U/ml) by engraftment of a hematopoietic cell line engineered to express this cytokine resulted in the development within 12-70 d of a fatal cachexia (54) .
Nonetheless, the two cytokines dearly share some biologic activities. The molecular basis for this overlap is likely to be related to the recent finding that both IL-11 and LIF transduce signals via a common transmembrane glycoprotein, gp130, originally identified as a component of the IL-6 receptor and now known be utilized by two other cytokines, oncostatin M and ciliary neurotrophic factor (55, 56) . Because the two cytokines share a common signal transduction pathway, any cell that expresses the binding subunits for IL-11 and LIF might be expected to behave similarly in response to both cytokines. It is also possible that the similar in vivo effects of high concentrations of IL-11 and LIF are due to one factor binding to the high affinity receptor of the other, as has been recently reported for oncostatin M which can bind to the high affinity LIF receptor (57) .
Alternatively, as it has also been demonstrated recently that both IL-11 and LIF induce the synthesis of IL-6 by human monocyte-macrophages (58, 59) , the question is raised whether some of the in vivo activities of these cytokines might be mediated in part by IL-6. A strong argument for relative lack of paracrine IL-6 involvement is the absence of the pathophysiology seen by us (22) in mice whose hematopoietic systems were reconstituted with bone marrow cells infected with a version of the MSCV vector carrying an IL-6 gene. Direct evidence that IL-6 does not play a major role in the in vivo IL-11 response are the findings that circulating levels of endogenous IL-6 were not elevated in MSCV-IL-11 mice compared with normal levels and that the abnormally high IL-11 levels did not induce detectable amounts of IL-6 mRNA in the spleen, a major organ source of IL-6 during endotoxemia (60) . The fact that plasma samples from MSCV-IL-11 mice treated with neutralizing antibody to IL-6 stimulated T10 cell proliferation more effectively than IL-11 alone does, however, indicates the presence of a novel activity in the plasma and leaves open the possibility that some of the changes observed might be ascribable to other factors acting secondarily (61).
IL-11 and Malignant
Growth. IL-11 was originally identified as a factor with mitogenic activity for IL-6-dependent murine Tl165 plasmacytoma ceils (4). We and others (62, and our unpublished results) observed that IL-11 also stimulates the proliferation of IL-6-dependent murine B9 hybridoma cells. In the absence of IL-6, IL-11 poorly supports the growth of either cell line and the vast majority of the cells die by apoptosis (63) . The T10 derivative of Tl165 ceils was established by selection for a variant that would grow in medium supplemented with only IL-11 (34) . We showed that IL-11 can act as an autocrine growth factor for both IL-11-dependent T10 cells and IL-11-responsive B9 cells. The in vitro mechanism of action of IL-11 on these IL-6-dependent murine B-lineage ceils appears to be direct and not due to the induction of endogenous IL-6. Previous results demonstrated that acquisition of autostimulatory IL-6 production enhanced the tumorigenicity of other IL-6-dependent murine plasmacytoma/hybridoma cells (64, 65) . The acquisition of the ability to produce autogenous IL-11 similarly potentiated the tumorigenicity of T10 and B9 cells, although, in the case of B9, the effect was less pronounced owing to the ready ability of these cells to grow in vivo in response to host IL-6 (42). These findings raise the possibility that IL-11 might be involved, conceivably in an autocrine manner, in the in vivo growth of some murine B cell tumors. At this time, however, the relevance of these observations to human tumor biology is unclear. In the human system, IL-6 has been demonstrated to promote the growth of multiple myeloma cells, either in a paracrine or autocrine fashion, but IL- 11 has not yet been found to be a myeloma growth factor (34) .
In contrast to the situation with established cell lines, accumulated data has indicated that autocrine stimulation alone is insufficient to transform primary cells (66) . Prolonged growth factor expression in vivo causes hyperplasia that infrequently leads to neoplastic transformation (67, 68) . In this series of transplants involving 10 primary and 20 secondary recipients of MSCV-IL-11-infected bone marrow, myeloid leukemia developed in two secondary recipients of bone marrow from the same donor. By comparison, none of over 300 BALB/c mice transplanted in our laboratory with bone marrow cells infected with other recombinant retroviruses have developed a myeloid malignancy (22, 32 , and our unpublished results). As the PGMD1 leukemic cell line requires a source of IL-3 for propagation, however, it has been difficult to demonstrate a direct stimulatory role for IL-11 (69) . Some degree of growth enhancement by IL-11 is assumed based on studies with normal progenitor cells (9) and more recent results showing that IL-11 acts synergistically with IL-3 or GM-CSF in stimulating the in vitro growth of the blast cells from patients with acute myeloblastic leukemia (70) . On the other hand, since a paracrine mechanism of growth promotion appears to be operating in vivo, it is possible that constitutive IL-11 synthesis by the leukemic cells might stimulate production of the necessary growth factors by host cells (71) . In any event, the MSCV-IL-11-marked clone represented the major population of donor cells in the spleen of primary mouse 74 but did not appear to be overtly malignant at that time. This suggests that whereas IL-11-supported expansion of progenitors might have initiated the process (72), secondary lesions were presumably necessary for progression to frank malignancy (73) .
The Bone Marrow Chimera Approach. We have demonstrated efficient infection of hematopoietic stem cells, precursors capable of long-term multilineage reconstitution of lethally irradiated primary and secondary recipients, by functional MSCV-IL-11 viruses. Although we have not shown that the same MSCV-IL-11 provirus is transcriptionally active in both myeloid and lymphoid progeny of a single stem ceil, the maintenance of high level expression of a nonselectable gene in vivo for (the equivalent of) at least 7 mo makes this in vivo gene transfer strategy a practical alternative to transgenic technology for analysis of gene function in the hematopoietic system.
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